Products Affected - Description
Sulfamethoxazole and trimethoprim oral suspension, Hi-Tech Pharmacal
200 mg/40 mg per 5 mL, 473 mL, cherry flavor (NDC 50383-0283-16) - discontinued
200 mg/40 mg per 5 mL, 473 mL, grape flavor (NDC 50383-0824-16) - discontinued
200 mg/40 mg per 5 mL, 20 mL unit dose, packages of 40, grape flavor (NDC 50383-0824-21) - discontinued
Sulfamethoxazole and trimethoprim oral suspension, Pharmaceutical Associates
200 mg/40 mg per 5 mL, 473 mL, cherry flavor (NDC 00121-4793-20) - discontinued
Reason for the Shortage
- Aurobindo could not provide a reason for the shortage.
- Hi-Tech Pharmacal discontinued all presentations of sulfamethoxazole and trimethoprim oral suspension in June 2014.
- Pharmaceutical Associated discontinued sulfamethoxazole and trimethoprim oral suspension in September 2013.
Sulfatrim oral suspension, STI Pharma
200 mg/40 mg per 5 mL, 473 mL, cherry flavor (NDC 54879-0007-16)
Sulfamethoxazole and trimethoprim oral suspension, Aurobindo
200 mg/40 mg per 5 mL, 473 mL, cherry flavor (NDC 65862-0496-47)
Estimated Resupply Dates
All presentations are currently available.
October 1, 2014; August 26, 2014; August 1, 2014; July 17, 2014; June 30, 2014; June 16, 2014 University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins